OxCan

The AI engine Fit Assessment

Beta

The company will be attending the 2024 Health Tech Forward Event

Blurb

OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection.

HQ Location

Oxford (United Kingdom)

Founded

2020

Employees

11 - 50

Total funding raised

$16.40M

Funding Status

Series A, $11.00M, January 9, 2025

Oxford Cancer Analytics Ltd (OXcan) is on a mission to enable curative cancer treatments through early detection. OXcan's machine learning platform enables minimally invasive and inexpensive cancer screening in high risk populations through analysing cancer materials shed into the blood. OXcan hopes to create a paradigm shift in screening and eventually replacing invasive tissue biopsy and expensive, complex imaging as the current standard of care. It is safer, cheaper, and detects cancers much earlier, when they are still curable.